Efficacy and Side Effects of Deferiprone (L1) in Thalassemia Patients Not Compliant with Desferrioxamine

Skip Nav Destination

Acta Haematol (1999) 101 (4): 173–177.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes

Richa Shah
Aashaka Shah
Sherif M. Badawy

Expert Review of Hematology (2023) 16 (2): 81.

An overview of the efficacy and safety of deferiprone in paediatric patients with congenital haemoglobinopathies and chronic iron overload

Adriana Ceci
Rosa Conte
Antonella Didio
Donato Bonifazi
Mariagrazia Felisi
Viviana Giannuzzi
Fedele Bonifazi

Expert Opinion on Orphan Drugs (2019) 7 (4): 181.

Deferiprone (GPO‐L‐ONE®) monotherapy reduces iron overload in transfusion‐dependent thalassemias: 1‐year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO‐L‐ONE; A001) from Thailand

Vip Viprakasit
Issarang Nuchprayoon
Ampaiwan Chuansumrit
Kitti Torcharus
Bunchoo Pongtanakul
Jiraporn Laothamatas
Somdet Srichairatanakool
Julaporn Pooliam
Siriwat Supajitkasem
Prapat Suriyaphol
Voravarn S. Tanphaichitr
Soodsarkorn Tuchinda

American Journal of Hematology (2013) 88 (4): 251.

Effectiveness of deferiprone in transfusion‐independent beta‐thalassemia/HbE patients

Krittapoom Akrawinthawong
Nithima Chaowalit
Thanasaporn Chatuparisuth
Noppadol Siritanaratkul

Hematology (2011) 16 (2): 113.

Experience with Combination Therapy of Deferiprone and Desferrioxamine in β-Thalassemia Major Patients with Iron Overload at Maternity and Children Hospital, Al Madinah Al Munawarah, Saudi Arabia

Zakaria Mohammad Al Hawsawi
Mona Hamza Sairafy
Ahmed Mohamed Tarawah
Mohammed Adnan Zolaly
Abdul Rahman Soad Al Hegaily

Journal of Taibah University Medical Sciences (2010) 5 (1): 27.

Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy

Xi-Ping Huang
Jake J. Thiessen
Michael Spino
Douglas M. Templeton

International Journal of Hematology (2010) 91 (3): 401.

Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other Conditions

George J Kontoghiorghes
Katia Neocleous
Annita Kolnagou

Drug Safety (2003) 26 (8): 553.

Multidentate pyridinones inhibit the metabolism of nontransferrin‐bound iron by hepatocytes and hepatoma cells

Anita C. G. Chua
Helen A. Ingram
Kenneth N. Raymond
Erica Baker

European Journal of Biochemistry (2003) 270 (8): 1689.

Monitoring long‐term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β‐thalassaemia major: application of SQUID biomagnetic liver susceptometry

Roland Fischer
Filomena Longo
Peter Nielsen
Rainer Engelhardt
Robert C. Hider
Antonio Piga

British Journal of Haematology (2003) 121 (6): 938.

Pharmacotherapy of iron overload in thalassaemic patients

Adriana Ceci
Mariagrazia Felisi
Vincenzo De Sanctis
Domenico De Mattia

Expert Opinion on Pharmacotherapy (2003) 4 (10): 1763.

Orally active iron chelators

L. Merson
N. Olivier

Blood Reviews (2002) 16 (2): 127.

Comparison between deferoxamine and deferiprone (L1) in iron‐loaded thalassemia patients

Ali Taher
Marwan Sheikh‐Taha
Suzanne Koussa
Adlette Inati
Roger Neeman
Fadi Mourad

European Journal of Haematology (2001) 67 (1): 30.

Chelation therapy in β-thalassemia: An optimistic update

Patricia J Giardina
Robert W Grady

Seminars in Hematology (2001) 38 (4): 360.

Iron chelation therapy

Chaim Hershko
A. Victor Hoffbrand

Reviews in Clinical and Experimental Hematology (2000) 4 (4): 337.

Efficacy and Side Effects of Deferiprone (L1) in Thalassemia Patients Not Compliant with Desferrioxamine

INFORMATION

ABOUT US

SERVICES FOR

Karger International

Efficacy and Side Effects of Deferiprone (L1) in Thalassemia Patients Not Compliant with Desferrioxamine

This Feature Is Available To Subscribers Only